<DOC>
	<DOCNO>NCT02657785</DOCNO>
	<brief_summary>This study suggest R-IDARAM combined intrathecal immunochemotherapy may high effective primary central nervous system lymphoma ( PCNSL ) patient .</brief_summary>
	<brief_title>Treatment PCNSL With R-IDARAM Intrathecal Immunochemotherapy</brief_title>
	<detailed_description>The investigator evaluate response rate , progression free survival ( PFS ) , overall survival ( OS ) , toxicity primary central nervous system lymphoma ( PCNSL ) systemic intrathecal immunochemotherapy defer radiotherapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Inclusion criterion : Newly diagnose histologically proven nonHodgkin 's lymphoma ( NHL ) . Exclusion criterion : Involved site brain , meninges , CSF , eye . Age le 18 year great 75 year . Inadequate bone marrow capacity ( define neutrophils &lt; 1.5 ×10^9/L , platelet &lt; 100 ×10^9/L , hemoglobin level &lt; 8 g/dL ) . Known cause immunosuppression ( ie , HIV type I infection ) . Any previous malignancy . Creatinine clearance 60 mL/min . Heart insufficiency ( NYHA IIIB IV ) . Uncontrolled infection . Noncompensated active pulmonary liver disease . Previously treat PCNSL , except corticosteroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>